Literature DB >> 30098162

Association of Fellow Eye With Study Eye Disease Trajectories and Need for Fellow Eye Treatment in Collaborative Initial Glaucoma Treatment Study (CIGTS) Participants.

Leslie M Niziol1, Brenda W Gillespie2, David C Musch1,3.   

Abstract

Importance: Clinicians would benefit from knowing the association of glaucomatous change in 2 eyes of the same patient. Objective: To estimate the time between initial glaucoma treatment of the study eye (SE) and the need for treatment of the fellow eye (FE) and to ascertain the concordance between rates of progression in SEs and FEs. Design, Setting, and Participants: In this post hoc analysis of participants from the Collaborative Initial Glaucoma Treatment Study, 607 participants with newly diagnosed open-angle glaucoma in 1 or both eyes were followed up for up to 11 years. An SE was designated at baseline and randomized to medical or surgical treatment. By protocol, FEs were treated when eligible or at physician discretion. Survival analysis methods were used to estimate the probability of FE treatment over time and to test baseline and time-dependent predictors of treatment. Disease trajectory was calculated with linear regression as the patient eye-specific slopes of mean deviation (MD) and intraocular pressure (IOP) over time, and correlations between SE and FE trajectories were calculated. Data were collected from October 1993 to December 2004. Data were analyzed from September 2012 to May 2018. Main Outcomes and Measures: Time to FE treatment and slopes over time of MD and IOP in SEs and FEs.
Results: Of the 607 included patients, 334 (55.0%) were male and 337 (55.5%) were white, and the mean (SD) age was 58.0 (10.9) years. A total of 291 FEs (47.9%) were treated at baseline, 123 (20.3%) were eventually treated, and 193 (31.8%) never received treatment. The probability of FE treatment for open-angle glaucoma was 0.57 at 1 year and 0.68 at 7 years after randomization. Characteristics significantly associated with an increased hazard of FE treatment included older age (hazard ratio [HR], 1.33; 95% CI, 1.08-1.64; P = .007), hypertension (HR, 1.76; 95% CI, 1.16-2.67; P = .008), higher IOP (HR, 1.24; 95% CI, 1.20-1.29; P < .001), large cup-disc ratio (HR, 1.40; 95% CI, 1.23-1.58; P < .001), and worse MD. Correlations in MD slopes between SEs and FEs initially, eventually, and never treated were 0.73, 0.71, and 0.34, respectively. Comparable correlations in IOP slopes were 0.57, 0.24, and 0, respectively. Conclusions and Relevance: Among patients with newly diagnosed open-angle glaucoma, almost half had initial treatment of both eyes. After 7 years, approximately two-thirds of patients had bilateral treatment. Of the variables predictive of FE treatment, modifiable factors included hypertension and IOP. Slopes of MD were similar between SEs and treated FEs. This implies that SE change is a harbinger of FE change and therefore warrants close surveillance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30098162      PMCID: PMC6583863          DOI: 10.1001/jamaophthalmol.2018.3274

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  18 in total

1.  The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients.

Authors:  D C Musch; P R Lichter; K E Guire; C L Standardi
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

2.  Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey.

Authors:  J M Tielsch; A Sommer; J Katz; R M Royall; H A Quigley; J Javitt
Journal:  JAMA       Date:  1991-07-17       Impact factor: 56.272

3.  Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment.

Authors:  J M Tielsch; J Katz; A Sommer; H A Quigley; J C Javitt
Journal:  Arch Ophthalmol       Date:  1995-02

4.  Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study.

Authors:  L Bonomi; G Marchini; M Marraffa; P Bernardi; R Morbio; A Varotto
Journal:  Ophthalmology       Date:  2000-07       Impact factor: 12.079

5.  Visual field progression in patients with initially unilateral visual field loss from chronic open-angle glaucoma.

Authors:  P P Chen; R J Park
Journal:  Ophthalmology       Date:  2000-09       Impact factor: 12.079

6.  Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension.

Authors:  Mae O Gordon; Valter Torri; Stefano Miglior; Julia A Beiser; Irene Floriani; J Philip Miller; Feng Gao; Ingrid Adamsons; Davide Poli; Ralph B D'Agostino; Michael A Kass
Journal:  Ophthalmology       Date:  2006-11-07       Impact factor: 12.079

7.  Risk factors for the development of glaucomatous visual field loss in ocular hypertension.

Authors:  H A Quigley; C Enger; J Katz; A Sommer; R Scott; D Gilbert
Journal:  Arch Ophthalmol       Date:  1994-05

8.  Open-angle glaucoma and systemic hypertension: the blue mountains eye study.

Authors:  Paul Mitchell; Anne J Lee; Elena Rochtchina; Jie Jin Wang
Journal:  J Glaucoma       Date:  2004-08       Impact factor: 2.503

9.  Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey.

Authors:  J M Tielsch; J Katz; A Sommer; H A Quigley; J C Javitt
Journal:  Arch Ophthalmol       Date:  1994-01

10.  Risk factors for open-angle glaucoma. The Barbados Eye Study.

Authors:  M C Leske; A M Connell; S Y Wu; L G Hyman; A P Schachat
Journal:  Arch Ophthalmol       Date:  1995-07
View more
  2 in total

1.  T and B Lymphocyte Deficiency in Rag1-/- Mice Reduces Retinal Ganglion Cell Loss in Experimental Glaucoma.

Authors:  Oliver W Gramlich; Cheyanne R Godwin; Neal D Heuss; Dale S Gregerson; Markus H Kuehn
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

2.  Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.

Authors:  David L Wirta; Yasuaki Kuwayama; Fenghe Lu; Hui Shao; Noriko Odani-Kawabata
Journal:  J Ocul Pharmacol Ther       Date:  2022-02-15       Impact factor: 2.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.